Understanding Key Differences Through Private Prescription
Why Compare Mounjaro and Wegovy Through Private Prescription UK?
The private prescription route offers distinct advantages when comparing Mounjaro and Wegovy for weight management. Unlike the NHS pathway requiring GP referrals and specialist weight management services with 6+ month waiting lists, private prescription allows direct access through clinical assessment. Both medications are prescription-only medicines requiring medical supervision, but private clinics can evaluate your suitability for either treatment based on individual medical history and preferences. The same genuine Novo Nordisk Wegovy and Eli Lilly Mounjaro supplied through NHS channels are available privately, ensuring identical medication quality and efficacy.
Private prescription also enables more flexible treatment selection when comparing why Mounjaro might suit some patients better than Wegovy. Your prescriber can consider factors like injection frequency preferences, storage requirements, and individual response patterns without the restrictive criteria often applied in NHS settings. This personalised approach means you receive the most appropriate medication for your circumstances rather than being limited by waiting list availability or rigid protocols.
Transparent Pricing and Value When Choosing Between Treatments
Understanding the cost implications helps inform decisions about why Mounjaro vs Wegovy selection matters for your budget. Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. New customers apply discount code FIRST40 at checkout, while returning patients use DOSE25 to reach these final prices. Bundle options like the Intro Duo (0.25mg & 0.5mg) at £169.99 provide treatment continuity across the initial 8-week period.
Mounjaro pricing follows a similar escalation pattern, though specific costs vary based on dose strength and availability. Both treatments require gradual dose increases over 16-20 weeks to reach maintenance levels, meaning total treatment investment spans several months regardless of which medication proves more suitable. The Gentle Start Trio bundle at £269.99 allows extended time at lower doses for patients requiring slower escalation, whilst the Ultimate Stability Trio provides three months of 2.4mg maintenance supply at £649.99.
Clinical Evidence Comparing Mounjaro and Wegovy Effectiveness
Clinical trials demonstrate different mechanisms of action when evaluating why Mounjaro vs Wegovy selection impacts treatment outcomes. Wegovy (semaglutide) showed approximately 15% average weight loss at 68 weeks in the STEP 1 trial, as reported by Wilding et al., NEJM, 2021. Mounjaro (tirzepatide) targets both GIP and GLP-1 receptors compared to Wegovy's single GLP-1 action, potentially offering different metabolic effects. However, direct head-to-head comparisons remain limited due to different trial designs and patient populations.
The SELECT cardiovascular outcomes trial demonstrated Wegovy's 20% reduction in major cardiovascular events (HR 0.80) in patients with established cardiovascular disease. Both medications require administration alongside a reduced-calorie diet and increased physical activity to achieve optimal results. Individual response patterns vary significantly, making clinical assessment essential to determine which treatment mechanism may prove more suitable for your specific medical profile and weight management goals.
How Wegovy Works in Your Body
Wegovy (semaglutide) functions as a GLP-1 receptor agonist, mimicking the natural incretin hormone GLP-1 produced in your intestines after eating. This prescription-only medicine binds to GLP-1 receptors in the brain's appetite control centres, reducing hunger signals and promoting feelings of fullness after smaller meals. The medication slows gastric emptying, meaning food remains in your stomach longer, contributing to sustained satiety between meals. Wegovy may also reduce food cravings and the reward response to high-calorie foods through its action on neural pathways. Weekly injections maintain steady medication levels, providing consistent appetite regulation throughout your treatment journey when used alongside dietary modifications and exercise.
Streamlined Ordering Process for Both Treatment Options
Accessing either Mounjaro or Wegovy through private prescription begins with our 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Qualified prescribers review your submission within 3 working days (or 24 hours with express service) to determine treatment suitability and medication selection. Once approved, your prescription-only medicine ships via next-day delivery using cold-chain transport to maintain medication integrity throughout transit. Our GPhC-registered pharmacy #9012878 ensures all medications meet MHRA quality standards with temperature monitoring from storage to your doorstep. Patient support continues throughout treatment with monitoring check-ins and dose escalation guidance as you progress through the structured dosing schedule.
Storage and Practical Considerations Affecting Your Choice
Storage requirements differ between Mounjaro and Wegovy, potentially influencing treatment selection for frequent travellers or those with limited refrigeration access. Wegovy offers superior storage flexibility, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both medications require refrigerated storage at 2-8°C before first use and utilise similar pre-filled injection pen systems for weekly administration. The FlexTouch pen system used by Wegovy provides dose precision with audible clicks confirming successful injection, whilst dose escalation follows a structured 16-week schedule from 0.25mg to 2.4mg maintenance dosing. Understanding these practical aspects helps inform decisions about why one treatment might integrate more seamlessly into your lifestyle than the other.
Dual-Mechanism Advantage: Why Some Patients Consider Mounjaro Superior to Wegovy
The fundamental difference explaining why some patients and prescribers favour Mounjaro over Wegovy lies in the dual-receptor mechanism of tirzepatide versus semaglutide's single-pathway approach. Mounjaro activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, potentially providing enhanced metabolic benefits through complementary pathways affecting blood sugar control, appetite regulation, and gastric emptying. This dual action may explain why certain patients experience different response patterns with Mounjaro compared to Wegovy, though individual variation remains significant.
However, the question of why Mounjaro might be considered better than Wegovy depends entirely on individual medical circumstances, tolerance profiles, and treatment goals. Private prescription allows your clinician to evaluate both options without the constraints of NHS formulary restrictions or availability issues. Some patients may find Mounjaro's dosing schedule or side effect profile more manageable, while others respond optimally to Wegovy's established GLP-1 pathway. Both medications are available from EverydayMeds, and your prescriber can help determine which treatment aligns best with your specific needs.
Making Your Treatment Decision with Expert Clinical Support
Rather than definitively stating why Mounjaro is better than Wegovy, evidence-based medicine suggests treatment selection should reflect individual patient factors including medical history, lifestyle requirements, and previous medication responses. Our clinical team evaluates multiple factors when recommending between these prescription-only medicines, considering contraindications, drug interactions, and your specific weight management objectives. Both treatments demonstrate significant efficacy in clinical trials when used alongside dietary modifications and exercise programs, with success rates varying based on patient adherence and individual metabolic factors. The private prescription advantage lies in having both options available with personalised clinical guidance, discount codes FIRST40 for new patients and DOSE25 for returning customers, and rapid access without NHS waiting periods. Contact our clinical team today to begin your assessment and discover which treatment option may prove most suitable for your weight management journey through our GPhC-registered service #9012878.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
